HER-2 negative breast cancer refers to breast cancer that does not have excess amounts of the human epidermal growth factor receptor 2 (HER2) protein. HER2-targeted therapies work well for HER2-positive cancers, but new treatment options are still needed for HER2-negative disease, which accounts for around 70% of all breast cancer cases. The HER-2 negative breast cancer treatment market has witnessed significant growth over the past few years, owing to the increasing number of patient diagnosed with HER-2 negative breast cancer and rising research and development activities in this field.

The global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 13,873.7 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
One of the major drivers boosting the growth of the HER-2 Negative Breast Cancer market is the increasing research and development activities by various key players in this field. As HER-2 negative breast cancer accounts for the majority of breast cancer cases, companies are focusing on developing advanced treatment solutions specific for HER-2 negative breast cancer. For instance, in September 2022, Daiichi Sankyo Company, Limited announced positive top-line results from the pivotal phase 3 DESTINY-Breast04 trial evaluating the investigational antibody-drug conjugate (ADC) datopotamab deruxtecan in patients with locally advanced or metastatic triple-negative breast cancer (TNBC), including patients whose tumors express low levels of PD-L1. If approved, datopotamab deruxtecan could provide an important new targeted treatment option for these patients. Additionally, favorable government initiatives and investment in research projects related to cancer therapeutics are also promoting the growth of this market.

SWOT Analysis

Strength: HER-2 negative breast cancer is the most common type of breast cancer accounting for around 70% of all breast cancer cases. Early diagnosis and availability of multiple treatment options are the major strengths. Newer targeted therapies provide better outcomes with minimal side effects.

Weakness: Limited awareness about early symptoms in developing nations leads to delayed diagnosis. High cost of targeted therapies is unaffordable for many patients. Multiple recurring mutations develop resistance to existing therapies.

Opportunity: Increasing focus on R&D of novel drug combinations and treatment strategies to overcome resistance. Growing elderly female population in Asia Pacific and Latin America increases potential patient base. Investments in cancer screening programs to enhance early detection rates.

Threats: Stringent regulations for drug approval delay market access. Patent expiries of blockbuster drugs increase competition. Covid-19 pandemic disrupted cancer screening, diagnosis and treatment services affecting demand.

Key Takeaways

The global HER-2 Negative Breast Cancer Market Growth is expected to witness high growth. North America currently dominates due to large patient population, higher healthcare spending and product approvals. However, Asia Pacific is likely to emerge as the fastest growing market supported by rising incidence, improving access to diagnostics and treatment.

Regional analysis
Asia Pacific is projected to register fastest growth during the forecast period supported by expanding patient pool, rising healthcare expenditures, increasing focus on cancer care and presence of generic drug manufacturers.

Key players
Key players operating in the HER-2 negative breast cancer market are Pfizer Inc., Novartis AG, Merck & Co. Inc., GSK PLC, AstraZeneca, Eli Lilly and Company, and Bristol-Myers Squibb Company (Celgene Corporation), among others.

Get More Insights On This Topic: https://blogger-veritas.blogspot.com/2023/12/rapid-growth-of-her-2-negative-breast.html